SynthesisSocial psychiatry and psychiatric epidemiology2020
Cannabis use in individuals at clinical high-risk for psychosis: a comprehensive review.
Synthesis in Social psychiatry and psychiatric epidemiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Predictors of transition in patients with clinical high risk for psychosis: an umbrella review.Translational psychiatry · 2023Pooled it
- Unhealthy behaviors associated with mental health disorders: a systematic comparative review of diet quality, sedentary behavior, and cannabis and tobacco use.Frontiers in public health · 2023Pooled it
- Global population attributable fraction of potentially modifiable risk factors for mental disorders: a meta-umbrella systematic review.Molecular psychiatry · 2022Pooled it
- Feasibility Trial of a Health Behaviours Promotion Group for Youth at Clinical High Risk for Psychosis.Early intervention in psychiatry · 2026Trial
- Cannabis and tobacco co-use predicts psychosis in clinical high risk cohorts.Nature. Mental health · 2026Article
- The Complex Relationship Between Cannabis Use and Mental Health: Considering the Influence of Cannabis Use Patterns and Individual Factors.CNS drugs · 2025Review
- Long-term use of cannabis-based medicines in two children with Tourette syndrome: a case report.Frontiers in psychiatry · 2025Article
- Occasional cannabis use is associated with higher premorbid functioning and IQ in youth at clinical high-risk (CHR) for psychosis: Parallel findings to psychosis cohorts.Schizophrenia research · 2024Article
- Exploring causal mechanisms of psychosis risk.Neuroscience and biobehavioral reviews · 2024Review
- Fronto-temporal cortical grey matter thickness and surface area in the at-risk mental state and recent-onset schizophrenia: a magnetic resonance imaging study.BMC psychiatry · 2024Article
- Cannabis use and psychotic disorders in diverse settings in the Global South: findings from INTREPID II.Psychological medicine · 2023Article
- Correlates of substance use in a large naturalistic cohort of young people with early and emerging psychosis.Social psychiatry and psychiatric epidemiology · 2023Article
- Influence of cannabis use on incidence of psychosis in people at clinical high risk.Psychiatry and clinical neurosciences · 2023Article
- Psychosocial factors associated with the risk of developing psychosis in a Mexican general population sample.Frontiers in psychiatry · 2023Article
- Neurobehavioral risk factors influence prevalence and severity of hazardous substance use in youth at genetic and clinical high risk for psychosis.Frontiers in psychiatry · 2023Article
- Stakeholder views on mindfulness for youth at risk for psychosis.International journal of mental health nursing · 2022Article
- Time-course of clinical symptoms in young people at ultra-high risk for transition to psychosis.Early intervention in psychiatry · 2022Article
- Cannabidiol (CBD) as a novel treatment in the early phases of psychosis.Psychopharmacology · 2022Review
- Cannabinoids, reward processing, and psychosis.Psychopharmacology · 2022Review
- Antipsychotics are related to psychometric conversion to psychosis in ultra-high-risk youth.Early intervention in psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purposeThe objectives of this review were to understand the prevalence of cannabis use and how cannabis is associated with transition to psychosis, symptoms, cognition, trauma and family history in clinical high risk (CHR) for psychosis individuals.
methodA systematic literature review was conducted to find studies that examined cannabis use in CHR individuals, with no limitations on the geographical area, and included publications up to November 2018. Studies were screened for inclusion based on detailed criteria, and data were extracted on cannabis use and associated outcomes. A quantitative synthesis by meta-analysis was performed where appropriate, otherwise, a qualitative synthesis was conducted.
resultsOverall, 36 studies met inclusion criteria with an average age of 20.1 years and 58.4% males. Prevalence of lifetime cannabis use was 48.7%, whereas current cannabis use was 25.8% and the prevalence of cannabis use disorder/abuse or dependence was 14.9% across the studies. All cannabis use results had statistically significant heterogeneity ranging from 75.7 to 92.8%. The most commonly reported association with cannabis use was transition to psychosis, although the pooled relative risk (RR) was not statistically significant (RR = 1.11, 95% confidence interval = 0.89-1.37). For all other outcomes including symptoms, cognition, trauma, and family history, the evidence was limited, and therefore, the results were synthesized qualitatively.
conclusionAlmost half of CHR individuals have ever used cannabis. However, cannabis use has not been thoroughly researched regarding frequency and dose of use, and how other factors, such as symptoms, are associated with cannabis in CHR individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.